103 results about "TLR3" patented technology

The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.

The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.

The present invention provides compositions comprising one or more RNAi agents (e.g., siRNAs, shRNAs, or RNAi vectors) for the treatment of conditions and diseases mediated by (e.g., featuring IgE-mediated hypersensitivity), as well as systems for identifying RNAi agents effective for this purpose. The compositions are suitable for the treatment of allergic rhinitis and / or asthma. In certain embodiments of the invention the RNAi agent is targeted to a transcript that encodes a protein selected from the group consisisting of the FCεRIα chain, the FCεRIβ chain, c-Kit, Lyn, Syk, ICOS, OX40L, CD40, CD80, CD86, Re1A, Re1B, 4-1BB ligand, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, CD83, SLAM, common γ chain, and COX-2. In addition, the invention provides RNAi agent / delivery agent compositions and methods of use. In certain embodiments of the invention compositions comprising an RNAi agent are delivered by the respiratory route.

Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of a TLR3 receptor by cancer cells.

The invention relates to the technical field of adipose mesenchymal stem cells in the technical field of cell therapy, in particular to a method for enhancing an immune regulating function and a migration capacity of adipose mesenchymal stem cells. Primary culture and secondary culture are performed to the adipose mesenchymal stem cells obtained through separation, and then short-time culture is performed by using culture medium containing low-concentration TLR3 activator Poly(I:C). After Poly(I:C) co-stimulation culture is performed, the obtained adipose mesenchymal stem cells with a brand new phenotype have a stronger migration capacity, the levels of secreting cytokine and chemotactic factor are changed and a stronger immunosuppressive function is reflected on the whole.

It is now recognized that chronic inflammation is an important risk factor for the development of cancer. The proinflammatory cytokine IL-6 is implicated in cancer because it is important for the activation of STAT, a key regulator of cancer growth, survival, metastasis, immune evasion and angiogenesis. Increased IL-6 and Stat-3 exists in vitro in pancreatic cancer, malignant melanoma, papillary thyroid cancer, breast cancer, colon cancer, and prostate cancer cells with high basal expression of Toll-like receptor 3 (TLR3) and Wnt5a. IL6 / STAT3 activation, mediated by overexpressed TLR3 signaling, appears important in the tumor growth process, it may increase Wnt5a signaling, and be associated with increased cellular growth and migration. Using a novel inhibitor of pathologic TLR3 signaling (5-phenylmethimazole [C10]) we have demonstrated decreases in these markers plus suppression of cell growth and migration in human pancreatic cancer, malignant melanoma, papillary thyroid cancer, breast cancer, colon cancer, and prostate cancer cells.

Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists, and methods of making and using the foregoing are disclosed.

The present invention relates to a method for the treatment and / or prophylaxis of a degenerative inflammatory process in a tissue of a subject, said method comprising increasing the activity of Toll-like receptor 3 (TLR3) in cells of said tissue. In a preferred embodiment, the TLR3 agonist is stathmin or stathmin-like proteins such as SCGIO, SCLIP or RB3.

The present disclosure relates to a method for inhibiting cancer tumor growth in a patient by administering to the patient a therapeutic monoclonal antibody specific for a tumor associated antigen in combination with at least one immunostimulatory compound, and at least one immune homeostatic checkpoint inhibitor. Also disclosed are uses, compositions and kits thereof.

The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.

Methods of enhancing the effectiveness of an antibody-based therapeutic agent are provided herein. The methods include administering an antibody-based therapeutic and a composition capable of preferentially activating monocytes or macrophages or preferentially depleting B10 cells to a subject in need of such treatment. The subject may have cancer, an autoimmune disease, an infectious disease or an immunodeficiency. The composition capable of preferentially activating monocytes or macrophages may be a TLR3 agonist. The composition capable of preferentially depleting B10 cells may be a CD19 antibody. Pharmaceutical compositions comprising an antibody-based therapeutic agent and a composition capable of preferentially activating monocytes or macrophages or preferentially depleting B10 cells are also provided.

Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

Agents interfering with translocation of Toll-like receptor 3 (TLR3), methods of making and using the foregoing are disclosed.

The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of a TLR3 receptor by cancer cells.

The invention relates to a detection system for detecting a human immune state and belongs to the technical field of gene detection. The detection system provided by the invention is used for detecting 20 genes, including IFI27, ISG15, IFI44L, RSAD2, HERC5, IFITM3, IFI44, IFIT3, EPSTI1, IFIT1, HP, ANXA3, ARG1, FCGR1B, S100A12, MMP9, IL18R1, TLR3, GYG1 AND FCGR1A in peripheral blood; the assessment for the human immune state can be realized in the manner of increasing or reducing the expression level of each gene; and the genes are utilized to guide accurate medical treatment, including disease accurate parting, prognosis, treatment tracking and therapeutic evaluation. The detection system has excellent clinic application values and wide application prospects.

The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.

The present invention relates to reagents and methods for the diagnosis, prognosis and treatment of cancer. Specifically, the present invention relates to the use of proteins encoding transmembrane superfamily member 6 (TM4SF6), synaptophysin-like protein (SYPL), stomatin-like 2 (STOML2), Ras-associated GTP-binding protein (RAGA), nucleotide-sensitive Chloride channel 1A (CLNS1A), prion protein (p27-30) (PRNP), guanine nucleotide-binding protein β2-like 1 (GNB2L1), guanine nucleotide-binding protein 4 (GNG4), integral membrane protein 2B (ITM2B), integral membrane protein 1 (ITM1), transmembrane 9 superfamily member 2 (TM9SF2), opiate receptor-like 1 protein (OPRL1), low-density lipoprotein receptor-related protein 4 (LRP4), human kidney Nucleic acid and amino acid sequences of glomerular epithelin 1 (GLEPP1), toll-like receptor 3 (TLR3), and / or zona pellucida glycoprotein 3A (ZP3) for early and advanced non-steroid-specific cancer diagnosis, cancer prognosis, and For screening therapeutic agents that modulate the gene expression and / or biological activity of the protein. The invention further relates to biotechniques designed to inhibit gene expression and / or biological activity of said proteins, including the use of agents identified in the screening assays described herein, vector delivery of antisense polynucleotide sequences, and the Antibody targeting the protein. In specific embodiments, the protein is of human origin.

Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

A novel form of Rugged dsRNA with a unique composition and physical characteristics was identified with high specificity of binding to TLR3, which conveys an important range of therapeutic opportunities. Unlike the previous known antiviral Ampligen® (poly I, poly C12,U) the new and improved form (poly I, poly C30,U) has a reduced tendency to form branched dsRNA which results in increased bioactivity due to an increased ability to bind TLR3 receptor. Pharmaceutical formulations containing the new nucleic acid as active ingredients and methods of treatment are also provided. The invention also provides a description of the physicochemical properties of this novel form of Rugged dsRNA and a method for its preparation in substantially pure form. DsRNAs acting thru TLR3 receptor activation are potent antiviral compounds as well as anticancer agents; also through secondary immunomodulation they can enhance the bioactivity of vaccines and also treat autoimmune disorders.

TLR3 glycosylation site muteins, nucleic acids encoding the muteins, and methods of modulating TLR3 activity in a cell are disclosed.

The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.

The present invention discloses a compound adjuvant for tuberculosis subunit vaccine, containing cationic liposome dimo-thylidioctyl ammonium bromide (DDA), TLR9 ligand CpG oligodeoxynucleotides 2395 and TLR3 ligand PolyICLC, and also provides the tuberculosis subunit vaccine and preparation method and application thereof. The beneficial effect of the invention is that the compound adjuvant for tuberculosis subunit vaccine provided by the present invention enhances the immunogenicity of the fusion protein of Mycobacterium tuberculosis, contributing to the induction of the tuberculosis fusion protein to Th1-type anti-tuberculosis immune response.

Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

The present invention relates generally to the fields of medicine. More specifically, the present invention relates to improved TLR3 agonists. The present invention provides novel dsRNA such as polyAU composition useful in the treatment of TLR3 related diseases, uses and preparations thereof.

The invention relates to agents and methods for the diagnosis, prognosis and treatment of cancer. Specifically, the invention relates to the use of nucleic and amino acid sequences encoding transmembrane superfamily member 6 (TM4SF6), synaptophysin like protein (SYPL), stomatin like 2 (STOML2), Ras related GTP binding protein RAGA), nucleotide sensitive chloride channel 1A (CLNS1A), prion protein (p27-30) (PRNP), guanine nucleotide binding protein beta 2-like 1 (GNB2L1), guanine nucleotide binding protein 4 (GNG4), integral membrane protein 2B (ITM2B), integral membrane protein 1 (ITM1), transmembrane 9 superfamily member 2 (TM9SF2), opiate receptor-like 1 protein (OPRL1), low density lipoprotein receptor-related protein 4 (LRP4), human glomerular epithelial protein 1 (GLEPP1), toll-like receptor 3 (TLR3), and / or zona pellucida glycoprotein 3A (ZP3) for the diagnosis of both early and late stage non-steroid specific cancers, cancer prognosis, as well as screening for therapeutic agents that regulate the gene expression and / or biological activity of said proteins. This invention further relates to the biological technologies designed to inhibit the gene expression and / or biological activity of said proteins including using agents identified in screening assays described herein, vector delivery of antisense polynucleotide sequences, and antibody targeting of said proteins. In specific embodiments, the proteins are of human origin.

Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

TOLL Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

The invention provides a fluorescent quantitative PCR detection method for a TLR3 (toll-like receptors) gene of a duck. The detection method comprises the following steps: by taking a recombinant plasmid Peasy-T5-TLR3 as a template, screening the optimum concentration of a primer, a fluorescent quantitative PCR reaction system and a reaction condition; by taking the recombinant plasmid as a standard substance, determining the OD260 value; according to the molecular weight and the mass concentration, calculating the copy concentration, diluting, carrying out FQ-PCR amplification; by taking logarithm of the recombinant plasmid copy number as axis X and circulating number of times as axis Y, establishing a standard curve; repeatedly verifying 1.0*10<3>-1*10<8> copy / microliter recombinant plasmid; carrying out FQ-PCR detection on the recombinant plasmid; and carrying out double verification on the specificity of the detection method by virtue of sequence alignment of a sample and the standard substance and a peak pattern of a solubility curve of the sample.

The invention discloses a gene chip for predicting RNA virus infected severe case. The gene chip comprises probes for capturing the following genes of ACE, ANGPT2, ASRD, CD55, FAAH, GLDC, IFITM3, IL1A, IL1B, IL1RN, IL6, IL10, IL17, IL28B, IRAK3, LGALS1, LRRC16A, MBL-2, NAMPT, NFE2L2, PI3, POPDC3, PPFIA1, SP-A2, SP-B, ST3GAL1, TLR1, TLR3, TMPRSS2, TNFA, VEGF, XKR3, ACYP2, BCL2L1, CTC1, CXCR4, NFY1,OBFC1, PXR, RTEL1, TERC, TERT, ZNF208, ZNF311, and ZNF676.